2020 Revenues ($USD) : $16,149,714,000
2020 Revenues (foreign currencies) : €14,154,000,000
2020 R&D spend : not available
2020 Number of Employees : not available
Fiscal Year End : 12/31/2020
Key People : Belén Garijo, chairman and CEO; Peter Guenter, member of the executive board, CEO healthcare; Matthias Heinzel, member of the executive board, CEO life science; Marcus Kuhnert, CFO

Significant milestones in 2020 for the Germany-based Merck included FDA approval of its immuno-oncology therapy Bavencio for advanced urothelial cancer treatment. Other approvals included the oral multiple sclerosis therapy Mavenclad, now registered in over 80 countries, including in the U.S. and EU. Merck also secured Japanese approval of its oncology precision medicine Tepmetko, which it developed in-house. –CN